Q4 saw a 45% net revenue increase to $10.1M, with prescription shipments up 25% and gross-to-net yield rising to 22%. Cost-saving initiatives, strong IP, and a scalable platform position the business for continued growth and strategic expansion.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.